Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention.
Vedana Therapeutics has raised $46.0M in total funding. The most recent round was Series A. The last funding was announced in June 2026.
Vedana Therapeutics's investors include Canaan Partners, Westlake Village BioPartners, Alexandria Venture Investments, Dawn Biopharma.
Vedana Therapeutics is headquartered in Seattle, United States.
Vedana Therapeutics is a Seattle biotechnology company developing next-generation antibody therapies for migraine prevention.
Vedana Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vedana Therapeutics — Funding & Investors." VCBacked, June 17, 2026, https://www.vcbacked.co/company/vedana-therapeutics. Accessed November 12, 2026.
VCBacked. (2026). Vedana Therapeutics — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/vedana-therapeutics
{{cite web |title=Vedana Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/vedana-therapeutics |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Vedana Therapeutics? Request a listing update